A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Stopped early · Phase 1

Conditions studied: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma

In brief

This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.

Key facts

Study ID

NCT03893682

Run by

Aptose Biosciences Inc.

People needed

36

Starts

2019-04-30

Expected to finish

2024-05-17

Last updated by the study team

2025-03-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Life expectancy of at least 2 months
• ECOG Performance Status ≤ 2
• Patients must be able to swallow capsules
• Adequate hematologic parameters, unless cytopenias are disease caused
• Adequate renal, liver and cardiac function parameters

You may not qualify if…

• Patients with GVHD requiring systemic immunosuppressive therapy
• Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinical significant disease related metabolic disorder
• Clinically significant intravascular coagulation
• Treatment with other investigational drugs within 14 days prior to first study treatment administration

Where it is running

• University of California Los Angeles — Los Angeles, California, United States
• Pacific Cancer Care — Monterey, California, United States
• Torrance Memorial Physician Network — Redondo Beach, California, United States
• UCSD Moores Cancer Center — San Diego, California, United States
• Sharp Clinical Oncology Research — San Diego, California, United States
• Ridley-Tree Cancer Center — Santa Barbara, California, United States
• St. Joseph Heritage Heathcare — Santa Rosa, California, United States
• Rocky Mountain Cancer Centers — Aurora, Colorado, United States
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States
• Orlando Health — Orlando, Florida, United States
• Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana, United States
• University of Maryland, Greenebaum Comprehensive Cancer Center — Baltimore, Maryland, United States
• The Center for Cancer and Blood Disorders a division of American Oncology Partners of Maryland, PA — Bethesda, Maryland, United States
• UMass Memorial Medical Center — Worcester, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Mayo Clinic Rochester — Rochester, Minnesota, United States
• SCL Health, St. Vincent Frontier Cancer Center — Billings, Montana, United States
• Morristown Medical Center — Morristown, New Jersey, United States
• Manhattan Hematology Oncology — New York, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Prisma Health - ITOR — Greenville, South Carolina, United States
• Carolina Blood and Cancer Care Associates — Rock Hill, South Carolina, United States
• Texas Oncology - Austin-Midtown — Austin, Texas, United States
• Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States
• Texas Oncology - Fort Worth Cancer Center — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.